WASHINGTON — A key House subcommittee chairwoman said on Thursday that she planned to hold hearings into the departure of Rick Bright, who said he was removed as the head of an agency involved in developing a coronavirus vaccine after he pressed for rigorous vetting of unproven drugs embraced by President Trump to combat the virus.

“I know that life is difficult for members to travel, but we can’t let that get in the way and I’m sure that other members would want to be a part of a hearing as well,” said Representative Anna G. Eshoo, the chairwoman of the House Energy and Commerce health subcommittee. Ms. Eshoo, a California Democrat, helped create the agency that Dr. Bright oversaw, the Biomedical Advanced Research and Development Authority.

The congresswoman spoke as Dr. Bright’s lawyers, in a statement, said that officials at the Health and Human Services Department, which BARDA is a part of, had made “demonstrably false” statements about Dr. Bright’s tenure, and that they planned to file whistle-blower complaints against the agency.

Dr. Bright was abruptly dismissed this week from his BARDA post and as the department’s deputy assistant secretary for preparedness and response, and was given a narrower job at the National Institutes of Health. In response, he issued a remarkable public statement accusing the Trump administration of putting cronyism over science, especially with two malaria drugs that the president has promoted as game changers in the treatment of the virus.